Cerity Partners
STRO icon

Cerity Partners’s Sutro Biopharma STRO Stock Holding History

Cerity Partners’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,806
Closed -$59.1K – 3009
2025
Q3 		$59.1K Sell
6,806
-3,738
-35% -$31.8K ﹤0.01% 2679
2025
Q2 		$75.3K Buy
10,544
+6,637
+170% +$54.3K ﹤0.01% 2517
2025
Q1 		$25.4K Buy
+3,907
New +$61.5K ﹤0.01% 2439
2024
Q4 		– Sell
-1,131
Closed -$39.1K – 2585
2024
Q3 		$39.1K Buy
+1,131
New +$44.3K ﹤0.01% 2495

Other funds holding STRO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Cerity Partners's STRO Position: Q4 2025 in Review

Cerity Partners sold out of Sutro Biopharma (STRO) in Q4 2025, closing a stake of 6,806 shares — an estimated $59.1K sold.

Cerity Partners first reported a position in STRO in Q3 2024 and held it in 4 quarters. The position peaked at $75.3K in Q2 2025. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

  • Cerity Partners reported no remaining Sutro Biopharma position as of Q4 2025 after selling out during the quarter.
  • Cerity Partners sold 6,806 Sutro Biopharma shares in Q4 2025, an estimated $59.1K.
  • Cerity Partners first reported a position in Sutro Biopharma in Q3 2024 and held it in 4 quarters.
  • Cerity Partners's Sutro Biopharma position peaked at $75.3K in Q2 2025.
  • 63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on Cerity Partners's 13F filing for Q4 2025, filed 11 Feb 2026.